Research from Bentley University's Center for Integration of Science and Industry shows public companies with price negotiable drugs under IRA were more profitable than comparable companies in the S&P500. The study also found that revenues from these drugs exceeded normal returns on investment before price negotiations began.
Research from Bentley University shows that biotechnology companies can maintain current levels of new drug approvals in face of global revenue reductions. Strategic distribution of cost reductions and continued investment in early-stage development by biotech firms sustain pipeline, contradicting industry claims.
A study from Bentley University's Center for Integration of Science and Industry found that US drug approvals were aligned with the US, but not global, burden of disease. The increasing number of expedited approval programs may make this gap worse, as these programs tend to favor conditions with lower disease burden.
The National Institutes of Health (NIH) invested approximately $164 billion in project funding prior to first drug approval, with only 0.59% ($0.95/$164 billion) associated with patents providing market exclusivity. This research highlights the limited public interest protections for NIH-funded research on new drugs approved between 20...
A new study by Bentley University reveals the NIH's significant investment in pharmaceutical innovation, with $8.1 billion spent on phased clinical trials between 2010-19. The funding represents only ~10% of reported industry costs for these trials, highlighting the public sector's limited contribution to drug development.
A Bentley University study shows that the National Institutes of Health (NIH) invests similarly to the pharmaceutical industry in bringing new drugs to market. The NIH spent $187 billion on research related to FDA-approved drugs between 2010-2019, with an average investment per approved drug of $1.7 billion.
A recent study published in PLOS ONE found that academic institutions receive significantly lower royalty rates, total payments, and pre-commercial payments for biotechnology licenses compared to commercial firms. The disparities were observed even after accounting for differences in product stage development.
A recent study published in Big Data & Society found that Democrats and Republicans in the US surveyed agree on the mathematical features of COVID-19 graphs, such as line slopes, but differ in their subjective interpretations. The researchers suggest that political affiliations may moderate how people interpret data, highlighting the i...
Researchers from Bentley University analyzed reader comments on two partisan news sites after a challenging news event, revealing obstacles to sense-making and breakdowns in deliberation. The study adds to the understanding of political discourse and polarization, highlighting the need for solutions to combat misinformation.
A study by Bentley University explores how the elderly use smart speaker technology at home, revealing heterogeneous use patterns. The results show that mornings and afternoons are more active, music and news are most prevalent, and simple commands dominate interactions.
A $17 billion investment in NIH-funded research on vaccine technologies provided a foundation for the rapid development of COVID-19 vaccines. The study highlights the critical role of government-funded research in ensuring vaccine readiness.
A large-scale study by Bentley University found that 78% of biotech companies completing Initial Public Offerings (IPOs) from 1997-2016 achieved product approvals. The majority of these approved products were small molecule drugs, accounting for 75% of phase 3 products and 78% of approvals.
A new study from Bentley University finds that emerging public biotech companies generated over $100 billion in shareholder value despite a high failure rate. The research compares the financial performance of biotech and non-biotech companies with similar IPO timelines, revealing comparable success rates and economic value creation.
Bentley University researchers are exploring ways to minimize recidivism among the homeless, with a focus on data-driven approaches. The team will leverage partnerships with community organizations and government agencies to develop analytical models and improve triage efforts at shelters.
Researchers from Bentley University explored a new approach to triage practices at homeless shelters, demonstrating the need for customizing work processes. The study employed an emerging technique called CMMN, which shows promise in supporting humanitarian settings.
Basic research funding for cancer therapies reached $64 billion, with the NIH contributing $20 billion and other institutes providing the majority of the remaining funds. This funding enabled the development of innovative immunotherapies for cancer.
A study by Bentley University reveals large pharmaceutical companies have higher profitability margins compared to other S&P 500 companies and technology firms. The research estimates cumulative revenues of $11.5 trillion and net income of $1.9 trillion over a 18-year period.
A study from Bentley University's Center for Integration of Science and Industry reveals that many undergraduate biology textbooks fail to provide context for applying science in business. This can lead to impaired student engagement and limited ability to apply science in the workforce, hindering the goals of science education.
A Bentley University study reveals the US government invested over $100 billion in basic research that led to 210 new medicines approved by the FDA. The National Institutes of Health (NIH) funded 84 innovative first-in-class drugs, which treat disease through novel biological mechanisms or targets.
The approval of Spinraza marks the emergence of a new class of biological products, following predictable patterns of innovation. Analysis of over 60,000 research publications reveals that successful product development characteristically follows the maturation of enabling research.
A new study from Bentley University and Tufts University tracks the progress of developing new therapies for cardiovascular disease, finding that median time to first approval is greater than 40 years. The authors propose accelerating drug development by optimizing basic research and synchronizing it with growth.
A new study from Bentley University found that most new drugs approved by the FDA since 2010 arose from basic scientific research initiated in the 1970s or 1980s. The development of targeted and biological therapeutics depends on achieving a certain level of maturation in basic science.